Moreover, in a preclinical murine model of lung cancer, TIGIT blockade can increase the efficacy of adoptive transfer therapies with engineered T cells [125], suggesting that, besides anti-PD-1 or PD-L1, the specific TIGIT targeting may be combined to other anti-cancer therapies. Here, TIGIT is linked to lung carcinoma.